GNC sells peptides and supplements over the counter. Prescription GLP-1 and clinical peptide programs operate in a different category that requires provider oversight, compliant intake, and pharmacy routing. FUSE gives operators the infrastructure to build and scale those programs alongside their existing supplement business. Prescription peptide programs typically generate higher revenue per patient than supplement purchases because of the clinical component. Margin depends on program pricing and platform fee structure — both of which operators confirm before launching. Supplement customers who convert to a prescription peptide program have a documented interest in the clinical category and convert at significantly higher rates than cold audiences.